We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 20.50 | 18.00 | 23.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMSUMM
Summit Therapeutics plc
('Summit' or the 'Company')
Summit Therapeutics to Participate in Jefferies 2018 London Healthcare
Conference
Oxford, UK, and Cambridge, MA, US, 7 November 2018 -- Summit
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism
antibiotic innovation, announces that management will conduct one-on-one
meetings at the Jefferies 2018 London Healthcare Conference, taking
place 14-15 November 2018 in London, UK. There will be no podium
presentation.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients, and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics for C.
difficile infection and gonorrhoea and are using our proprietary Discuva
Platform to expand our pipeline. For more information, visit
www.summitplc.com and follow us on Twitter @summitplc.
Contacts
Summit
Glyn Edwards / Richard Pye (UK
office) Tel: 44 (0)1235 443 951
Erik Ostrowski / Michelle Avery
(US office) +1 617 225 4455
Cairn Financial Advisers LLP
(Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate
Finance
Tom Salvesen, Corporate Broking
Panmure Gordon (Joint Broker) Tel: +44 (0)20 7886 2500
Freddy Crossley, Corporate Finance
James Stearns, Corporate Broking
MSL Group (US) Tel: +1 781 684 6557
mailto:summit@mslgroup.com
Jon Siegal summit@mslgroup.com
---------------------------------
Consilium Strategic Communications
(UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Jessica Hodgson mailto:summit@consilium-comms.com
/ summit@consilium-comms.com
---------------------------------
Lindsey Neville
-END-
(END) Dow Jones Newswires
November 07, 2018 07:00 ET (12:00 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Summit Therapeutics Chart |
1 Month Summit Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
